-First Post Here’s the real reason why sociologist Ashis Nandy should be in the dock of public criticism. There is almost no evidence whatsoever to substantiate his observation that the backward classes and Dalits are seen as more corrupt because they are less good at hiding it than their upper class compatriots. Nandy is facing police investigations for saying at the Jaipur Literary Festival (JLF) last week that “most of the corrupt...

-Live Mint Income-tax department says firm had underpriced intragroup share transfer by Rs 15,000 cr and evaded taxes consequently The Indian arm of Royal Dutch Shell Plc , Shell India Pvt. Ltd, has been accused by the income-tax (I-T) authorities of underpricing an intragroup share transfer by ` 15,000 crore and consequently evading taxes, said a person familiar with the development.   Following the notice, which is one of the biggest transfer pricing orders...

-The Guardian Inequity such as that symbolised by Antilla, the world's richest home, thwarts poverty reduction – and policymakers must act If you want a glimpse across the yawning chasm that separates the world's super rich from the ultra poor, there's no better place than Mumbai's Altamount Road. Look up and you'll see Antilla, the world's most expensive home. With spectacular ocean views, swimming and gym facilities, and no fewer than three helipads,...

-The Hindu One of the most prominent features of India’s middle-class-driven public culture has been an obsession about our GDP growth rate, and a facile equation of that number with a sense of national achievement or impending arrival into affluence. In media headlines, political speeches, and everyday conversations, the GDP growth rate number — whether it is five per cent or eight per cent or whatever — has become a staple...

-The Economic Times Pharmaceutical multinationals have begun using the Right to Information law to launch pre-emptive legal action against local generic players to protect the market of patented drugs and delay the entry of low cost generic medicines in the 60,000-crore domestic drug market. MNCs are using such information to sue generic firms even at a stage when their marketing approval is still pending or during the few months' window between the...